荟萃分析:重新定义杂合子α1-抗胰蛋白酶缺乏症的肝病风险
该系统综述与荟萃分析纳入26项研究共27,933例杂合子与547,961例对照,评估SERPINA1杂合基因型(MZ、SZ)的肝脏结局。结果显示杂合子肝酶轻度升高,纤维化、肝硬化和肝移植的比值比显著增加(OR分别为2.14、2.24、2.28)。结论认为杂合子SERPINA1基因型是真实的肝脏风险状态,应视为中等外显率的肝病易感基因型。
要点
- MZ/SZ杂合子肝酶轻度升高,异常ALT、AST、ALP的OR分别为1.18、1.16、1.41。
- 杂合子纤维化、肝硬化、肝移植风险显著增加,OR分别为2.14、2.24、2.28。
- 杂合子与对照组BMI和脂肪变性风险无显著差异。
核心结论
- 杂合子SERPINA1基因型(MZ、SZ)是真实的肝脏风险状态,效应量与已知遗传和环境决定因素相当。
- MZ/SZ杂合性应在慢性肝病风险评估中被认定为中等外显率的肝脏易感基因型。
研究设计与样本
- 纳入26项报告MZ或SZ基因型肝脏结局的研究,共27,933例杂合子和547,961例对照。
- 合并均值差(MD)和比值比(OR),使用既定工具评估偏倚风险(PROSPERO CRD420251165586)。
主要发现
- BMI(MD -0.09 [-0.20-0.02])和脂肪变性风险(OR 1.09 [0.74-1.60])在组间相当。
- 杂合子肝酶轻度升高:ALT MD 1.03 [0.41-1.66];AST MD 0.68 [0.51-0.85];ALP MD 2.58 [1.58-3.58]。
- 异常ALT(OR 1.18 [1.11-1.25])、AST(OR 1.16 [1.07-1.26])、ALP(OR 1.41 [1.18-1.68])的比值比升高。
- 纤维化(OR 2.14 [1.52-3.02])、肝硬化(OR 2.24 [1.73-2.91])、肝移植(OR 2.28 [1.45-3.59])的比值比显著增加。
临床怎么用
- 在慢性肝病风险评估中,应将MZ/SZ杂合性视为中等外显率的肝脏易感基因型。
- 对MZ/SZ杂合子应关注肝酶及纤维化、肝硬化风险,必要时进行相应评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Heterozygous SERPINA1 genotypes (MZ, SZ) have historically been regarded as carrier states with limited liver relevance. Emerging evidence suggests increased liver injury, but the magnitude of risk remains uncertain. We synthesized evidence on heterozygous SERPINA1 liver phenotypes to quantify this risk. METHODS: We performed a systematic review of bibliographic databases from inception to 21 October 2025 for studies reporting liver outcomes in MZ or SZ genotypes. Outcomes were grouped into metabolic comorbidities, biochemical markers, and clinical liver disease. Random-effects meta-analyses pooled mean differences (MDs) and odds ratios (ORs); risk of bias was assessed with established tools (PROSPERO CRD420251165586). RESULTS: Twenty-six studies including 27,933 heterozygotes and 547,961 controls met inclusion criteria. BMI (MD -0.09 [-0.20-0.02]) and steatosis risk (OR 1.09 [0.74-1.60]) were comparable between groups. Heterozygotes had modestly higher liver enzymes (ALT MD 1.03 [0.41-1.66]; AST MD 0.68 [0.51-0.85]; ALP MD 2.58 [1.58-3.58]) and higher odds of abnormal ALT (OR 1.18 [1.11-1.25]), AST (OR 1.16 [1.07-1.26]), and ALP (OR 1.41 [1.18-1.68]). They had significantly increased odds of fibrosis (OR 2.14 [1.52-3.02]), cirrhosis (OR 2.24 [1.73-2.91]), and liver transplantation (OR 2.28 [1.45-3.59]). CONCLUSIONS: Heterozygous SERPINA1 genotypes are bona fide liver risk states, with effect sizes comparable to established genetic and environmental determinants. MZ/SZ heterozygosity should be recognized as moderate-penetrance liver susceptibility genotypes in chronic liver disease risk assessment.
引用
- Syanda AM, Georgantaki D, Linn RTT, et al. Meta-Analysis: Redefining Liver Disease Risk in Heterozygous Alpha-1 Antitrypsin Deficiency. Aliment Pharmacol Ther. 2026. PMID: 42437373. doi:10.1111/apt.70814
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。